Antiadrenergic therapy in the control of atrial fibrillation

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 10, Issue SUPPL. 1, 2005, Pages

  Naccarelli, Gerald V ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Atrial fibrillation; Carvedilol; Digoxin; Heart failure; Rate control; Rhythm control

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIGITALIS; DIGOXIN; DIHYDROPYRIDINE; DILTIAZEM; DOFETILIDE; METOPROLOL; PLACEBO; SOTALOL; VERAPAMIL; WARFARIN; ADRENERGIC RECEPTOR BLOCKING AGENT;

ADRENERGIC SYSTEM; BRADYCARDIA; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENTIATION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART HEMODYNAMICS; HEART PROARRHYTHMIA; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; MORTALITY; NONHUMAN; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINUS RHYTHM; SUDDEN DEATH; SYMPATHETIC TONE; TACHYCARDIA INDUCED CARDIOMYOPATHY; THROMBOSIS; TORSADE DES POINTES; TREATMENT OUTCOME; ARTICLE; ATRIAL FIBRILLATION; DISEASE COURSE; HEART ARRHYTHMIA; RISK ASSESSMENT; RISK REDUCTION;

EID: 20544461943     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/10742484050100i405     Document Type: Review

References (51)

1. American Heart Association. Heart Disease and Stroke Statistics-2005 Update. Dallas, TX: American Heart Association; 2005
2. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 98(10):946-952, 1998
3. Allessie MA, Boyden PA, Camm AJ, et al. Pathophysiology and prevention of atrial fibrillation. Circulation 103(5):769-777, 2001
4. Hynes BJ, Luck JC, Wolbrette DL, et al. Atrial fibrillation in patients with heart failure. Curr Opin Cardiol 18(1):32-38, 2003
5. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: Epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 91(6A):2D-8D, 2003
6. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation 84(1):40-48, 1991
7. Naccarelli GV, Hynes J, Wolbrette DL, et al. Atrial fibrillation in heart failure. J Cardiovasc Electrophysiol 14(suppl):s281-s286, 2003
8. Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 32(3): 695-703, 1998
9. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 107(23):2920-2925, 2003
10. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311(13):819-823, 1984
11. Mann DL, Kent RL, Parsons B, Cooper G. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 85(2):790-804, 1992
12. CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 353(9146):9-13, 1999
13. MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353(9169):2001-2007, 1999
14. Pozzoli M, Cioffi G, Traversi E, et al Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: A prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 32(1):197-204, 1998
15. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: A meta-analysis. Circulation 101(10): 1138-1144, 2000
16. Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 69(19):1570-1573, 1992
17. Zipes DP. Atrial fibrillation. A tachycardia-induced atrial cardiomyopathy. Circulation 95(3):562-564, 1997
18. Goette A, Staack T, Rocken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 35(6):1669-1677, 2000
19. Morillo CA, Klein GJ, Jones DL, Guiraudon CM. Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation 91(5):1588-1595, 1995
20. Ausma J, Wijffels M, Thone F, et al. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 96(9):3157-3163, 1997
21. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different sort. Circulation 100(1):87-95, 1999
22. Wijffels MC, Kirchhof CJ, Borland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92(7):1954-1968, 1995
23. Wasmund SL, Li JM, Page RL, et al. Effect of atrial fibrillation and an irregular ventricular response on sympathetic nerve activity in human subjects. Circulation 107(15):2011-2015, 2003
24. Denker S, Lehmann M, Mahmud R, et al. Facilitation of ventricular tachycardia induction with abrupt changes in ventricular cycle length. Am J Cardiol 53(4):508-515, 1984
25. Ramaswamy K. Beta blockers improve outcome in patients with heart failure and atrial fibrillation: U.S. Carvedilol Study. Card Electrophysiol Rev 7(3):229-232, 2003
26. Prystowsky EN, Benson DW Jr, Fuster V, et al. Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 93(6): 1262-1277, 1996
27. Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 20(3):527-532, 1992
28. Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish investigations of arrhythmia and mortality on dofetilide (DIAMOND) substudy. Circulation 104(3):292-296, 2001
29. Bolognesi R. The pharmacologic treatment of atrial fibrillation. Cardiovasc Drugs Ther 5(3):617-628, 1991
30. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation 104(17):2118-2150, 2001
31. Olshansky B, Rosenfeld LE, Warner AL, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: Approaches to control rate in atrial fibrillation. J Am Coll Cardiol 43(7):1201-1208, 2004
32. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347(23):1825-1833, 2002
33. Okcun B, Yigit Z, Arat A, Kucukoglu SM. Comparison of rate and rhythm control in patients with atrial fibrillation and nonischemic heart failure. Jpn Heart J 45(4):591-601, 2004
34. Roy D. Rationale for the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. Card Electrophysiol Rev 7(3):208-210, 2003
35. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 38(7):2101-2113, 2001
36. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334(21):1349-1355, 1996
37. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344(22):1651-1658, 2001
38. Packer M, Fowler MB, Roecker EB, et al. Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation 106(17):2194-2199. 2002
39. Farshi R, Kistner D, Sarma JS, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: A crossover open-label study of five drug regimens. J Am Coll Cardiol 33(2):304-310, 1999
40. Meng F, Yoshikawa T, Baba A, et al. Beta-blockers are effective in congestive heart failure patients with atrial fibrillation. J Card Fail 9(5):398-403, 2003
41. Joglar JA, Acusta AP, Shusterman NH, et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: Retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 142(3):498-501, 2001
42. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 103(10): 1428-1433, 2001
43. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 362(9377):7-13, 2003
44. Swedberg K, Olsson L, Hanrath P, et al. Importance of atrial fibrillation in chronic heart failure in patients treated with beta-blockers: results from COMET. Eur Heart J [Epub ahead of print at http://eurheartj.oupjournals.org/cgi/ rapidpdf/ehi166v1] 2005
45. Agarwal AK, Venugopalan P. Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy. Eur J Heart Fail 3(4): 437-440, 2001
46. Khand AU, Rankin AC, Martin W, et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 42(11):1944-1951, 2003
47. McMurray J, Kober L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 45(4):525-530, 2005
48. Merritt JC, Niebaur M, Tarakji K, et al. Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation. Am J Cardiol 92(6):735-736, 2003
49. Karle CA, Kreye VA, Thomas D, et al. Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc Res 49(2):361-370, 2001
50. Cheng J, Niwa R, Kamiya K, et al. Carvedilol blocks the repolarizing K+ currents and the L-type Ca2+ current in rabbit ventricular myocytes. Eur J Pharmacol 376(1-2):189-201, 1999
51. Singh BN. Antiarrhythmic drugs: A reorientation in light of recent developments in the control of disorders of rhythm. Am J Cardiol 81(6A):3D-13D, 1998